Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Mossaheb

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Der Nervenarzt|June 3, 2005
[Early recognition and intervention for schizophrenia]N Mossaheb, G Wiesegger, G P Amminger, et al.
BMC Psychiatry|June 3, 2023
Psychotic-like experiences in non-clinical subgroups with and without specific beliefsB Hinterbuchinger, M Koch, M Trimmel, et al.
Psychopharmacology|September 7, 2006
In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopramN Klein, J Sacher, T Geiss-Granadia, et al.
Schizophrenia Research|October 23, 2017
The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quoM J McHugh, P D McGorry, H P Yuen, et al.
Schizophrenia Research|December 13, 2018
Dynamic prediction of transition to psychosis using joint modellingH P Yuen, A Mackinnon, J Hartmann, et al.
NPJ Schizophrenia|June 27, 2018
NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical courseB Nelson, G P Amminger, H P Yuen, et al.
Schizophrenia Research|December 24, 2019
Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomesS Youn, L J Phillips, G P Amminger, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Der Nervenarzt|June 3, 2005
[Early recognition and intervention for schizophrenia]N Mossaheb, G Wiesegger, G P Amminger, et al.
BMC Psychiatry|June 3, 2023
Psychotic-like experiences in non-clinical subgroups with and without specific beliefsB Hinterbuchinger, M Koch, M Trimmel, et al.
Psychopharmacology|September 7, 2006
In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopramN Klein, J Sacher, T Geiss-Granadia, et al.
Schizophrenia Research|October 23, 2017
The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quoM J McHugh, P D McGorry, H P Yuen, et al.
Schizophrenia Research|December 13, 2018
Dynamic prediction of transition to psychosis using joint modellingH P Yuen, A Mackinnon, J Hartmann, et al.
NPJ Schizophrenia|June 27, 2018
NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical courseB Nelson, G P Amminger, H P Yuen, et al.
Schizophrenia Research|December 24, 2019
Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomesS Youn, L J Phillips, G P Amminger, et al.
Pageof 1